Literature DB >> 17318324

Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?

Valerie Touitou1, Damien Sene, Christine Fardeau, Thi-Huong-Du Boutin, Pierre Duhaut, Jean-Charles Piette, Phuc LeHoang, Patrice Cacoub, Bahram Bodaghi.   

Abstract

Successful therapy based on the use of interferon-alpha has been reported in different types of severe chronic uveitis. The immunomodulatory effects of this drug, combined with its antiviral properties seem to contribute to its efficacy in the treatment of different forms of severe and refractory uveitis such as Vogt-Koyanagi-Harada disease, Behçet-associated uveitis, or even human herpes virus 8 (HHV-8) associated uveitis. At the same time, severe ocular complications have been reported in patients treated with interferon-alpha for chronic viral hepatitis C. Among these complications, six cases of Vogt-Koyanagi-Harada-like disease have been described.We report a small case series of two patients with refractory Vogt-Koyanagi-Harada disease, treated with interferon-alpha and discuss the potential benefits or detrimental role of interferon therapy in these patients.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17318324     DOI： 10.1007/s10792-007-9040-2

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN： 0165-5701            Impact factor:   2.029


  35 in total

1.  Interferon alpha 2a in IRPB-derived peptide-induced EAU--part I.

Authors:  Nicole Stübiger; Isabel J Crane; Ina Kötter; Graeme R Lamont; Margot Zoeller; Ursula Günthert; John V Forrester; Manfred Zierhut; Rainer H Stiemer
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

2.  Influence of interferon-alpha on lymphocyte subpopulations in Behçet's disease.

Authors:  Michaela Treusch; Nicole Stübiger; Reinhard Vonthein; Manuela Baur; Silvia Koch; Ilhan Günaydin; Lothar Kanz; Manfred Zierhut; Ina Kötter
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

3.  The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease.

Authors:  N Bouchenaki; C P Herbort
Journal:  Ophthalmology       Date:  2001-01       Impact factor: 12.079

4.  Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.

Authors:  B Wechsler; B Bodaghi; D L Huong; C Fardeau; Z Amoura; N Cassoux; J C Piette; P LeHoang
Journal:  Ocul Immunol Inflamm       Date:  2000-12       Impact factor: 3.070

5.  Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.

Authors:  G Antonelli; E Simeoni; F Bagnato; C Pozzilli; O Turriziani; R Tesoro; P Di Marco; C Gasperini; C Fieschi; F Dianzani
Journal:  J Neurol Sci       Date:  1999-10-15       Impact factor: 3.181

Review 6.  Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.

Authors:  Akinori Kasahara; Atsushi Hiraide; Naruya Tomita; Hiromi Iwahashi; Akihisa Imagawa; Nobuyuki Ohguro; Shuji Yamamoto; Eiji Mita; Norio Hayashi
Journal:  J Gastroenterol       Date:  2004-11       Impact factor: 7.527

7.  Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis.

Authors:  Emmanuelle Brasnu; Bertrand Wechsler; Alain Bron; Frederic Charlotte; Philippe Bliefeld; Phuc Lehoang; Anne-Genevieve Marcelin; Bahram Bodaghi
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

8.  Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.

Authors:  R Pellicano; A Smedile; S Peyre; M Astegiano; G Saracco; R Bonardi; M Rizzetto
Journal:  Minerva Gastroenterol Dietol       Date:  2005-03

9.  Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.

Authors:  M Treusch; R Vonthein; M Baur; I Günaydin; S Koch; N Stübiger; A K Eckstein; H-H Peter; T Ness; M Zierhut; I Kötter
Journal:  Rheumatology (Oxford)       Date:  2004-07-13       Impact factor: 7.580

10.  Kinetics of intraocular cytokines in the suppression of experimental autoimmune uveoretinitis by type I IFN.

Authors:  A A Okada; H Keino; J Suzuki; J Sakai; M Usui; J Mizuguchi
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823
View more
  5 in total

Review 1.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

2.  Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.

Authors:  Abdulrahman M Al-Muammar; Tariq M Al-Mudhaiyan; Mohammed Al Otaibi; Ayman Abdo; Ahmed M Abu El-Asrar
Journal:  Int Ophthalmol       Date:  2010-02-23       Impact factor: 2.031

Review 3.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 4.  Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

Authors:  Carl P Herbort; Ahmed M Abu El Asrar; Joyce H Yamamoto; Carlos E Pavésio; Vishali Gupta; Moncef Khairallah; Ilknur Tugal-Tutkun; Masoud Soheilian; Masuru Takeuchi; Marina Papadia
Journal:  Int Ophthalmol       Date:  2016-11-14       Impact factor: 2.031

5.  Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients.

Authors:  Shizhao Yang; Tianyu Tao; Zhaohuai Li; Binyao Chen; Zhaohao Huang; Xiuxing Liu; He Li; Lihui Xie; Wen Feng; Wenru Su
Journal:  Ann Transl Med       Date:  2022-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.